Melanoma-associated antigen 3 clinical trials
A product of Melanoma-Associated Antigen 3; its studies count on that page too.
How each study uses melanoma-associated antigen 3 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2005 (2)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2011 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 7
M.D. Anderson Cancer Center (2) · University of Chicago (2) · University of Maryland, Baltimore (1) · University of Arkansas (1) · Charite University, Berlin, Germany (1)
Often tested with
Tested in the same studies.
Astuprotimut-r (3) · Interleukin-2 (2) · HPV16 Vaccine (1) · Interleukin-12 (1) · MART-1 Antigen (1) · GP-100 antigen (1) · Melanocyte Protein PMEL (1) · NA17 (1)
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Melanoma-Associated Antigen 3
Studies
Open first, then newest update. How each study uses melanoma-associated antigen 3 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCICompletedPhase 2M.D. Anderson Cancer CenterNCT01266603Written as recMAGE-A3 + AS15
- 0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and NeckCompletedPhase 1University of Maryland, BaltimoreNCT00257738Written as MAGE-A3
- Melanoma Vaccine With Peptides and LeuprolideCompletedPhase 2M.D. Anderson Cancer CenterNCT00254397Written as MAGE-3 Peptide
- Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic MelanomaCompletedPhase 1/2University of ChicagoNCT00002952Written as recombinant MAGE-3.1 antigen
- Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic MelanomaCompletedPhase 2University of ChicagoNCT00203879Written as MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
- Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple MyelomaCompletedPhase 2/3University of ArkansasNCT00090493Written as MAGE-A3
- Multiepitope Peptide Vaccination in MelanomaStatus unknownPhase 2Charite University, Berlin, GermanyNCT00153569Written as Tyrosinase, MAGE-3, GnTV
Given beside what is tested · 3 — melanoma-associated antigen 3 is usual care or a partner of the new treatment
- Tumor and Vaccine Site With a Toll Like Receptor (TLR) AgonistCompletedPhase 2M.D. Anderson Cancer CenterNCT00960752Written as MAGE-3
- Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic MelanomaTerminatedPhase 2National Cancer Institute (NCI)NCT01307618Written as Recombinant MAGE-3.1 Antigen
- Vaccine Therapy in Treating Patients With Stage IIC-IV MelanomaCompletedPhase 2University of Southern CaliforniaNCT00085189Written as recombinant MAGE-3.1 antigen
Codes
What other systems call melanoma-associated antigen 3 · ClinicalTrials.gg INT017715
- UNII (FDA) QU3R73GB8NMELANOMA-ASSOCIATED ANTIGEN 3One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | QU3R73GB8N | MELANOMA-ASSOCIATED ANTIGEN 3 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.